Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | PTEN negative |
Gene Variant Detail | |
Relevant Treatment Approaches | Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT01870726 | Phase Ib/II | Buparlisib + Capmatinib | Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma | Terminated | USA | NLD | ESP | DEU | 1 |
NCT05038839 | Phase I | Cabozantinib + Pamiparib | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | Recruiting | USA | 0 |
NCT04493853 | Phase III | Abiraterone + Capivasertib Abiraterone | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281) | Active, not recruiting | USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
NCT06239467 | Phase I | OKI-219 + Trastuzumab OKI-219 Fulvestrant + OKI-219 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01) | Recruiting | USA | ESP | 1 |